-LCB-_-LRB-
Cortisone-resistant_JJ
bronchial_JJ
asthma_NN
-RCB-_-RRB-

There_EX
is_VBZ
general_JJ
agreement_NN
on_IN
the_DT
inflammatory_JJ
pathogenesis_NN
of_IN
bronchial_JJ
asthma_NN
:_:
an_DT
accumulation_NN
of_IN
activated_VBN
eosinophils_NNS
,_,
degranulated_VBN
mast_NN
cells_NNS
,_,
T_NN
lymphocytes_NNS
and_CC
in_IN
very_RB
severe_JJ
forms_NNS
,_,
granulocytes_NNS
has_VBZ
constantly_RB
been_VBN
found_VBN
in_IN
the_DT
bronchial_JJ
mucosa_NN
._.

In_IN
allergic_JJ
bronchial_JJ
asthma_NN
,_,
inflammation_NN
seems_VBZ
to_TO
be_VB
orchestrated_VBN
predominantly_RB
by_IN
a_DT
subset_NN
of_IN
T_NN
lymphocytes_NNS
,_,
with_IN
a_DT
phenotype_NN
similar_JJ
to_TO
the_DT
Th2_NN
subset_NN
able_JJ
to_TO
produce_VB
IL-4_NN
and_CC
IL-5_NN
._.

Although_IN
corticosteroids_NNS
are_VBP
the_DT
most_RBS
potent_JJ
therapeutic_JJ
agents_NNS
used_VBN
for_IN
this_DT
disease_NN
,_,
their_PRP$
anti-inflammatory_JJ
effect_NN
differs_VBZ
from_IN
patient_NN
to_TO
patient_NN
._.

Some_DT
criteria_NNS
which_WDT
can_MD
be_VB
used_VBN
to_TO
define_VB
steroid-resistant_JJ
bronchial_JJ
asthma_NN
are_VBP
listed_VBN
here_RB
._.

This_DT
review_NN
analyzes_VBZ
various_JJ
molecular_JJ
alterations_NNS
responsible_JJ
for_IN
the_DT
deficient_JJ
response_NN
to_TO
corticosteroid_NN
treatment_NN
observed_VBN
in_IN
steroid-resistant_JJ
bronchial_JJ
asthmatic_JJ
subjects_NNS
._.

New_JJ
knowledge_NN
on_IN
the_DT
mechanism_NN
of_IN
steroid_NN
resistance_NN
may_MD
have_VB
important_JJ
implications_NNS
for_IN
the_DT
treatment_NN
of_IN
chronic_JJ
asthma_NN
and_CC
other_JJ
diseases_NNS
._.

